In the News
An Epic Approach To Liquid Biopsy
San Diego, MDDI – The liquid biopsy space continues to attract investors and bring in financings that are typically above the average amount medtech firms are able to raise. Epic Sciences is the latest liquid biopsy company to obtain funding and has raised about $52 million in a series E round.
CTC AR-V7 Assay Shows Promise as Treatment Guide in mCRPC
San Diego, OncLive — An assay for nuclear-localized androgen receptor splice variant 7 (AR-V7) protein in circulating tumor cells (CTCs) identified patients with metastatic castration-resistant prostate cancer (mCRPC) who had better outcomes from treatment with taxanes, and those who did better with androgen receptor-signaling (ARS) inhibitors.
Blood test predicts treatment response for metastatic prostate cancer
San Diego, European Pharmaceutical Review — Testing could lead to extension of life through improved clinical decision-making by identifying patients who need to switch from targeted hormonal therapy to chemotherapy…
Study: Blood Test for Prostate Cancer Can Guide Therapy, Extend Lives
San Diego, Xconomy — Blood tests for cancer, known as liquid biopsies, have become available in recent years to guide treatments for people already diagnosed. But how useful are they? A paper published last week in the journal JAMA Oncology makes the case that one such test, Oncotype DX AR-V7 Nucleus Detect, might be worth its $3,980 price tag.
Study Validates Oncotype DX AR-V7 Chemo Prediction
New York, GenomeWeb – A newly published multi-institutional cohort study has validated Epic Sciences' circulating tumor cell-based AR-V7 test, now marketed by Genomic Health as Oncotype DX AR-V7 Nucleus Detect. The blinded study, published in JAMA Oncology, enrolled 142 patients with metastatic castration-resistant prostate cancer who were treated with either taxanes or androgen receptor signaling (ARS) inhibitors and observed for up to 4.3 years.
AR-V7+ CTCs Predicted Worse PFS, OS in mCRPC
San Diego, Cancer Network — Detection of circulating tumor cells (CTCs) positive for the nuclear-specific AR-V7 protein was an independent predictor of shortened progression-free survival (PFS) and overall survival (OS) when treating metastatic castration-resistant prostate cancer (mCRPC) with abiraterone or enzalutamide, according to results of the PROPHECY study (abstract 5004). The findings were presented at the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO), held June 1–5 in Chicago.
Tests identify who would benefit from advanced prostate cancer therapies
San Diego, MedicalXpress – Two blood tests can predict which subset of men with advanced prostate cancer will likely not benefit from anti-androgen therapies, providing doctors and patient added clarity on treatment options, according to a study led by Duke Cancer Institute. The blood tests, dubbed "liquid biopsies", detect androgen receptor splice variant-7 (AR-V7) circulating in prostate tumor cells. The presence of this variant indicates a poor response to new androgen receptor drugs that are used to treat recurrent, metastatic prostate cancer.